Malaria Clinical Trial
Official title:
Targeted Parasite Elimination in the Human and Mosquito to Reduce Malaria Transmission: A Cluster Randomised Controlled Factorial Design Trial of Reactive Focal Drug Administration (rfMDA) Versus Reactive Case Detection (RACD), With and Without Reactive Vector Control (RAVC), From the Low Endemic Setting of Namibia
This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus reactive case detection (RACD), and 2) reactive IRS (indoor residual spraying) versus control on the incidence of malaria in Namibia.
In recent years, many countries, including Namibia, have experienced reductions in malaria
transmission in association with the scale-up of effective interventions and are now moving
towards malaria elimination. In malaria control, the goal is to reduce the clinical burden of
malaria. In malaria elimination, the aim is to interrupt transmission, and it becomes
necessary to address not only symptomatic malaria, but also asymptomatic infections that
contribute to transmission. Since malaria transmission is highly geographically
heterogeneous, elimination activities should target hot spots, or areas where the risk of
future infection is highest. Hence, in the transition from control to elimination, enhanced
surveillance and response is necessary to target hot spots with interventions to interrupt
transmission.
Reactive case detection (RACD), active surveillance in communities around passively detected
cases, is a recommended elimination strategy to identify secondary cases and hot spots.
However, RACD can be labour-, time-, and cost- intensive, and misses people who are absent
during screening or refuse to have their blood drawn. Furthermore, both microscopy and rapid
diagnostic tests (RDTs) utilized in RACD have shortcomings, for instance, the suboptimal
sensitivity of RDTs for low parasite density and non-falciparum infections. Polymerase chain
reaction (PCR) offers markedly improved sensitivity over RDTs but requires hours of
processing time, sophisticated technical skills, and expensive equipment. Given these
limitations, presumptive treatment may be a more feasible and effective strategy to reduce
and interrupt transmission.
Reactive focal mass drug administration (rfMDA), a form of presumptive treatment, has been
used successfully in China to overcome some of the weaknesses of RACD. rfMDA targets
remaining reservoirs of infection in low endemic settings by treating everyone at high risk
(subjects residing around an index case), rather than rely on RDT results, which have been
shown to miss infections. In a low transmission setting such as Namibia, only a small
proportion of the populations is at high risk of infection, therefore, only a small number of
people need to be targeted (perhaps 20-50 people). Additional indoor residual spraying (IRS)
targeted to homes in high risk locations can also be implemented.
rfMDA is a promising strategy, but evidence does not yet exist to prove its efficacy in
Africa. Questions remain about where to target rfMDA, what drugs to use, and whether drugs
should be used alone or in combination with additional vector control. For rfMDA to be most
successful, it is necessary to kill parasites in the human as well as the vector population
of the target area. However, one challenge of pre-transmission season IRS is that it is
difficult to predict where future infections will occur. A reactive approach, in conjunction
with the pre-transmission approach, will ensure coverage of effective vector control in the
highest risk areas. Further, if there is unknown resistance to the insecticide used during
pre-transmission season, the subsequent reactive use of a different, and presumably effective
insecticide, will provide better protection.
In this study the investigators will utilise a cluster randomized controlled study design to
evaluate rfMDA in response to a passively identified index case and compare it to RACD. The
investigators will study each intervention (rfMDA, RACD) both with and without additional
focal insecticide spraying.
56 enumeration areas (EAs) within catchment areas of 11 study health facilities will be
randomized to one of four intervention arms:
1. RACD only
2. RACD with RAVC
3. rfMDA only
4. rfMDA with RAVC
A rapid reporting surveillance system will capture confirmed, passively identified cases at
all study health facilities, and those cases will trigger an intervention by the study team
if located in one of the study EAs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02527005 -
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
|
Phase 1 |